BCR Antibody (N-term) Blocking Peptide
€293.00
In stock
SKU
AC-BP7113a
Background:
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac.
Other Names: Breakpoint cluster region protein, Renal carcinoma antigen NY-REN-26, BCR, BCR1, D22S11
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7113a was selected from the N-term region of human BCR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P11274
Gene ID: 613
Gene Name: BCR (HGNC:1014)
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Burchert, A., et al., Blood 103(9):3480-3489 (2004).H, et al., Exp. Hematol. 32(5):476-482 (2004).Salesse, S., et al., Leukemia 18(4):727-733 (2004).Klein, F., et al., J. Exp. Med. 199(5):673-685 (2004).Hsu, H.C., et al., J. Lab. Clin. Med. 143(2):125-129 (2004).
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac.
Other Names: Breakpoint cluster region protein, Renal carcinoma antigen NY-REN-26, BCR, BCR1, D22S11
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7113a was selected from the N-term region of human BCR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P11274
Gene ID: 613
Gene Name: BCR (HGNC:1014)
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Burchert, A., et al., Blood 103(9):3480-3489 (2004).H, et al., Exp. Hematol. 32(5):476-482 (2004).Salesse, S., et al., Leukemia 18(4):727-733 (2004).Klein, F., et al., J. Exp. Med. 199(5):673-685 (2004).Hsu, H.C., et al., J. Lab. Clin. Med. 143(2):125-129 (2004).
| Is Featured? | No |
|---|
Write Your Own Review